NAS
IBRX icon

Nykredit A/S’s ImmunityBio IBRX Stock Holding History

Nykredit A/S’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.5K Buy
+11,140
New +$84.3K ﹤0.01% 1325

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Nykredit A/S's IBRX Position: Q2 2026 in Review

Nykredit A/S opened a new position in ImmunityBio (IBRX) in Q2 2026: 11,140 shares worth $97.5K. The stake represents ﹤0.01% of the portfolio and ranks #1325 among its holdings.

316 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Nykredit A/S held 11,140 shares of ImmunityBio worth $97.5K as of Q2 2026.
  • ImmunityBio was a new Nykredit A/S position in Q2 2026.
  • ImmunityBio made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1325 holding.
  • 316 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.